


Biosample Access

What Type of Biosamples are available for HD Research?
Ask us – we will help you!




* Very limited resource. Analyses ongoing. Access subject to review by Prof. Sarah Tabrizi and CHDI CMO Cristina Sampaio

| Study | Summary | Duration | # participants | Participant segment | Lymphoblastoid cell lines LCLs | DNA from whole blood | Ficoll PBMCs | Buffy coat | Plasma | CSF | Cells from CSF | Serum | PAX gene RNA | Buccal swabs | Other |
|-------------------------|--|-------------|-------------------|--|--------------------------------|--|-----------------------------|------------------|--------------------------|---------------|----------------|---------------|----------------------|--------------|--|
| Enroll-HD | Prospective, open-ended, multi-national, multi-center observational study without experimental treatments. | 2012- | 25,900 | <ul style="list-style-type: none"> Manifest HD Pre-manifest HD Genotype negative Genotype unknown Family Control Community Control | Yes, BL 2012 – Mar 2018 | Yes, BL 2012 - | Yes, All 2012 - | No | Yes, EDTA July 2019 - | No | No | No | No | No | No |
| REGISTRY | Prospective, open-ended, European, multi-center observational study without experimental treatments. | 2004 - 2017 | 13,000 | <ul style="list-style-type: none"> Manifest HD Pre-manifest HD Genotype negative Genotype unknown Family Control Community Control | Yes, BL 2005 – Sep 2015 | Yes BL: 2005 – Sep 2015 FUP: Apr 2010 – Sep 2015 | Yes, All 2005 – Sep 2015 | No | No | No | No | No | No | No | No |
| HDCSF/ HDClarity | Study to collect high-quality CSF samples for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. Enroll-HD platform study. | 2017- | 600 Goal: 1200 | <ul style="list-style-type: none"> Early Pre-manifest HD Late Pre-manifest HD Early Manifest HD Mod Manifest HD Late Manifest HD Control | No | No | No | No | Yes, LiHep 2017 - | Yes 2017 - | Yes 2017 - | Yes 2017 - | No | No | No |
| HDYAS* | Study to identify and describe the earliest signs of HD-related brain changes and functional impairments. | 2017 - 2019 | 131 | <ul style="list-style-type: none"> Early Pre-manifest HD Control | No | No | No | No | Yes, LiHep | Yes | Yes | Yes | No | No | No |
| TRACK-HD | Multi-site international study aiming to establish what measurements were the best to use as 'outcome measures' for clinical trials in HD. | 2008-2011 | 402 | <ul style="list-style-type: none"> Pre-manifest Early Manifest Control | Yes, BL 2008 | Yes BL: 2008 FUP: 2011 | No | Yes, All EDTA | Yes, All EDTA | No | No | No | Yes - 2008 - 2010 | No | No |
| TRACK-ON | Extension of TRACK-HD | 2012 – 2014 | 245 | <ul style="list-style-type: none"> Pre-manifest Early Manifest Control | No | Yes, All | Yes, All CPT | No | Yes, All CPT | No | No | No | Yes - 2014 | Yes, All | No |
| MTM-HD | Multi Tissue Monitoring. Improved insight into disease-specific pathway/network alterations; Analysis of tissue samples from participating individuals will help to identify HD-related signatures | 2015 - 2017 | 60 | <ul style="list-style-type: none"> Pre-manifest Early Manifest Control | No | Yes | No | Yes | Yes, EDTA | No | No | No | No | Yes | Fibroblasts Myoblasts iPS Primary: Skin Muscle Fat |

BL: Baseline; FUP: Follow Up

Process to access biosamples



Biosample request managers: Non-renewable: Mette Gilling Nielsen, mette.gilling@enroll-hd.org; Renewable: Christine Capper-Loup, christine.capper-loup@enroll-hd.org